CSAAI 2019 A Midsummer Night's Wheeze

June 21, 2019 to June 23, 2019

This program is designed to allow attendees to continue exploring the immunology frontier.  Covered topics include current and emerging treatments in atopic dermatitis, translational targets for new asthma therapeutics and drug desensitization to chemotherapeutic agents and biologics.  In addition, recent advances in allergy diagnostic testing, an update on food allergy treatment as well as considerations in choosing a treatment for food allergy will also be presented.

This activity supported by independent educational grants from CSL Behring, Grifols, GSK, Stallergenes Greer, Kaleo 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medication Education (ACCME) through joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and California Society of Allergy, Asthma and Immunology. The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians. 

Designation

The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 11 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Target Audience

Allergists
Immunologists

Learning Objectives

 At the conclusion of the meeting, participants should be able to:

  • Discuss the efficacy of allergen immunotherapy (AIT)
  • Identify the optimal regimen and duration of AIT
  • Understand the safety of AIT
  • Discuss specific IgE testing
  • Discuss serum allergen-specific IgE tests:  difference amongst assays
  • Discuss component-resolved diagnostic testing - diagnostic utility I food allergy evaluation
  • Discuss component-resolved diagnostic testing - utility in alleged immunotherapy
  • Describe the role of filaggrin in AD
  • Identify the factors in the pathogenesis of AD
  • Evaluate the role of the microbiome in AD
  • Identify common pitfalls in the treatment of AD
  • Describe the rationale for an extended therapeutic ladder in refractory disease
  • Evaluate upcoming treatments and those that have no proven benefit
  • Learn methods for evaluation patient-reported outcome in antibody deficiency patients
  • Learn the present options in treating your patients and how to consider navigating them
  • Learn the current challenges diagnosis antibody deficiency disorders
  • Learn the spectrum and current context for primary immunodeficiencies
  • Learn the basis, rationale and best approach to applying genomic diagnosis in primary immunodeficiency
  • Define the term precision approaches to disease
  • Characterize the utility of biomarkers that can predict therapeutic responses to biologic therapies
  • Identify the value of pharmacodynamic biomarkers in determining target engagement and improvement in asthma care
  • Describe a new paradigm that explains irreversible airway obstruction and remodeling in severe asthma
  • Identify new approaches to maximize bronchodilation in asthma
  • Define the molecular mechanisms by which steroid act acutely to improve asthma outcomes
Additional information
Disclosure: 

Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months.  All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations.  It is required that disclosure be provided to the learners prior to the start of the activity.  Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist.  Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.  Disclosure in no way implies that the information presented is biased or of lesser quality.  It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations.  Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

The individuals listed below disclose the following financial relationships:

Matthew Greenhawt, MD – Speaker

Speaker: ACAAI, Aimmune, Allergy & Asthma Network, Before Brands, Canadian Society of Allergy & Clinical Immunology, DBV, EAACI, Eastern

Allergy Society, FL Society of Allergy & Immunology, Kansas City Allergy Society, Medscape, N. CA Allergy Society, Thermo Fisher

Advisory Board: Aimmune, Allergenis, Aquestive, DBV, Genentech, Intrommune, Kaléo, Monsanto, Nestlé, Nutricia, Prota, Sanofi/Genzyme

Consultant: Aimmune, Canadian Transportation Agency, Thermo Fisher

Principal Investigator: AHRQ, DBV BIOPOT

Employment: ACAAI, University of Colorado

 

Peter Lio, MD – Speaker

Speaker: Regeneron/Sanofi/Genzyme, Pierre-Fabre

Consultant: Regeneron/Sanofi/Genzyme, Abbvie, AOBiome, Eli Lilly, Galderma, Johnson & Johnson, L’Oreal, Theraplex (OTCs), Pierre-Fabre, Micreo (no U.S. product at this time)

Advisory Board: Regeneron/Sanofi/Genzyme, Abbvie, Derma Vant, Eli Lilly, Galderma, Johnson & Johnson, L’Oreal, Theraplex (OTCs), IntraDerm and Realm Therapeutics

Investigator: Regeneron/Sanofi/Genzyme, Abbvie, AOBiome

 

J. Allen Meadows, MD, FACAAI – Speaker

Speaker: Optinose, Pfizer, Teva

Advisory Board: GSK, Greer

 

Jordan S. Orange, MD, PhD – Speaker

Consultant: Shire, Grifols

Scientific Advisory Board: ADMA Biologics

Author/Editor: UpToDate

 

Reynold A. Panettieri, Jr., MD – Speaker

Consultant: AstraZeneca, MedImmune, RIFM, Equillium, Theravance, Boehringer-Ingelheim

Advisory Board: AstraZeneca, MedImmune, RIFM, Equillium, Theravance, Boehringer-Ingelheim

Research Grant: AstraZeneca, MedImmune, RIFM, Equillium, Teva

Speaker: AstraZeneca, Genentech, Sanofi-Regeneron

 

Madeline Ramos, MD – Presenter, Planner, Reviewer

Speaker: Teva

 

Raffi Tachdjian, MD – Planner

Speaker: Shire, Pharming, Regeneron/Sanofi, CSL Behring

Consultant: Shire, Pharming, Regeneron/Sanofi, CSL Behring

Clinical Trial: Shire, Biocryst

 

Sonal Patel, MD – Planner

Speaker: Sanofi/Regeneron, Pfizer

 

Steven Meltzer, MD, MBA – Planner

Investigator: Regeneron, AstraZeneca, Sanofi/Genzyme, Novartis, Pfizer

 

 

The following have no relevant financial relationships to disclose:

Linda Cox, MD – Speaker

David Edward Sloane, MD – Speaker

Barbara Weissman, MD – Speaker

Victoria Eng, MD – Speaker

Fernanda Delgado, MD – Speaker

Kevin Pedrotti – Speaker

Christina Schwindt, MD – Presenter, Planner

Robert Eitches, MD – Presenter, Planner, Reviewer

Marilyn Li, MD – Presenter, Planner

LanAnh Do, MD – Planner

Vincent Tubiolo, MD – Planner

Karol Anderson – Planner

 

 

Course summary
Available credit: 
  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Attendance
Course opens: 
06/21/2019
Course expires: 
06/23/2020
Event starts: 
06/21/2019 - 1:50pm
Event ends: 
06/23/2019 - 11:45pm
Rating: 
0

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership the American College of Allergy, Asthma and Immunology and the California Society for Allergy, Asthma and Immunology. The American College of Allergy, Asthma and Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 11 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity

Available Credit

  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Attendance

Accreditation Period

Course opens: 
06/21/2019
Course expires: 
06/23/2020
Please login or create an account to take this course.